Neuroepithelioma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Neuroblastoma is a malignant tumor that arises from neural crest cells, which give rise to the sympathetic nervous system, and occurs mainly in children. The prognosis of neuroblastoma is affected by various genetic anomalies, such as amplification of the oncogene MYCN, numerical abnormalities of chromosomes and segmental chromosomal anomalies (including loss from 1p, from 11q, or gains of 17q). Diagnosis is based on elevated metabolites of urinary catecholamines and imaging of the initial tumor by ultrasound, brain scan, or MRI. MIBG scintigraphy and medullary analysis are useful for detecting metastases. Nephroblastoma is a differential diagnosis. Bone pain and limp can be misinterpreted as synovitis of the hip, and bilateral peri-orbital hematomas should not be mistaken for maltreatment. The prognosis of neuroblastoma is poor for approximately 60% of children over one year of age who present with metastatic disease at diagnosis, even with intensive treatment. The five-year survival rate for children over one year of age ranges from 95% for some localized tumors to 30% in cases of metastatic neuroblastoma.

·       It represents about 10% of solid tumors in infants and children under 15, with an annual incidence of approximately 1/70,000 in children in this class of age.

Thelansis’s “Neuroepithelioma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuroepithelioma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Neuroepithelioma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Neuroepithelioma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Neuroepithelioma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

 

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033